Seminal Trial Series: Nivolumab and Non-Small Cell Lung Cancer with Dr. Julie Brahmer

Podcast | English | 2024 | 32 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

Today’s episode of Lung Cancer Considered is part of our special series on seminal trials in thoracic oncology, focusing on the phase I study of the PD-1 inhibitor nivolumab. Hosts Dr. Narjust Florez and Dr. Stephen Liu discuss that study with guest Dr. Julie Brahmer from Johns Hopkins University. This podcast features surprise guest interviews with several doctors who were mentored by Dr. Brahmer.

Podcast Hosts:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA
Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA

Podcast Guests:

Julie Brahmer, MD, Professor of Oncology at Johns Hopkins University and Co-Director of the Upper Aerodigestive Department within the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, USA
Elsa Anagnostou, MD, Co-Director, Johns Hopkins Lung Cancer Precision Medicine Center of Excellence, Baltimore, MD, USA
Patrick Forde, M.B.B.Ch., Director of Thoracic Oncology - Clinical Research Program and Associate Professor, John Hopkins University, Baltimore, MD, USA
Jarushka Naidoo, MD, Medical Oncologist, Beaumont Hospital, Dublin, Ireland